BioInvent's BI-1910 Data Validates TNFR2 as a Novel Immunotherapy Approach in Advanced Solid Tumors: Phase 1 Data at SITC 2025

Twelve patients achieved stable disease, whereof five with disease control lasting over six months; this correlates with ...